DUBLIN--(BUSINESS WIRE)--The "Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period.
Factors such as increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market. However, the lack of a unified set of regulations for therapeutic peptides is expected to restrain the growth of this market during the forecast period.
By technology, the peptide synthesis market is segmented into solid-phase, liquid-phase, and hybrid & recombinant technology. Solid-phase synthesis is associated with a number of advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. Such advantages are expected to drive the adoption of solid-phase synthesis.
By end user, the market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic and research institutes. The contract development and manufacturing organizations segment is expected to grow at the highest CAGR during the forecast period. The increasing demand for cost-effective peptide synthesis services in drug development activities and life science research is driving the growth of this segment.
Key Topics Covered
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Peptide Synthesis Market, By Product
7 Peptide Synthesis Market, By Technology
8 Peptide Synthesis Market, By End User
9 Peptide Synthesis Market, By Region
10 Competitive Landscape
11 Company Profiles
- Advanced Chemtech
- Anaspec (A Subsidiary of Kaneka Eurogentec S.A.)
- Bachem Holdings
- CEM Corporation
- Genscript Biotech
- Gyros Protein Technologies
- Merck KGaA
- NEP (New England Peptide)
For more information about this report visit https://www.researchandmarkets.com/research/8qvgh9/global_426_4_mn?w=4